^
    Back
    Association details:
    Biomarker:RUNX1 mutation
    Cancer:Chronic Myelomonocytic Leukemia
    Drug:Venclexta (venetoclax) (Bcl2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN

    Excerpt:
    ...- a history of mutation in TP53, RUNX1, or ASXL1...
    Trial ID:
    NCT03613532
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2020
    Title:

    2189 Activity of Venetoclax-Based Therapy in CMML and CMML with Blast Transformation

    Published date:
    11/04/2020
    Excerpt:
    We retrospectively reviewed pts with CMML, both with and without BT, treated with VEN-based therapy…VEN was given in combination with HMA in 76% of the CMML group, whereas in the BT group it was partnered with HMA (47%), intensive chemotherapy (20%), or other agents (33%)....NPM1 mutations predict for CR and RUNX1 mutations are associated with a trend to higher ORR.
    Secondary therapy:
    Hypomethylating agent; Chemotherapy